Indication
In combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is indicated for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy.
Medicine details
- Medicine name:
- pembrolizumab (Keytruda)
- SMC ID:
- SMC2829
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 13 April 2026
- SMC meeting date:
- TBC
- Patient group submission deadline:
- 02 February 2026